Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.

Literature DB >> 17675264

Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.

Juan-Manuel Sancho¹, Guillermo Deben, Anne Parker, José-Luis Piñana, Simon Bolam, Eva Sánchez-García, Eugenio Giménez, Teresa Pascual, Pascual Fernández-Abellán, Luis Palomera, Josep-Maria Ribera.

Abstract

Intrathecal (IT) depot liposomal cytarabine is useful in solid tumors or lymphomatous meningitis, but has scarcely been used in central nervous system (CNS) involvement in acute leukemia. We report the results of compassionate therapy with IT depot liposomal cytarabine in 10 patients with acute myeloid leukemia with CNS involvement. Five of 6 cases receiving this drug as the only IT therapy and the remaining 4 receiving it as adjuvant therapy to other CNS-directed therapies showed clearance of cerebrospinal fluid blast cells, with sustained response in 5 and mild side effects. Systemic therapy was given concomitantly in all cases, with high-dose cytarabine in 6. Clinical trials should establish the role of IT liposomal cytarabine in leukemic meningitis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17675264 DOI： 10.1532/IJH97.E0704

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

10 in total

1. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe.

Authors: Danish Mazhar; Justin Stebbing; Rachel Lewis; Mark Nelson; Brian G Gazzard; Mark Bower
Journal: Blood Date: 2006-04-15 Impact factor: 22.113

2. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

Authors: Elias Jabbour; Susan O'Brien; Hagop Kantarjian; Guillermo Garcia-Manero; Alessandra Ferrajoli; Farhad Ravandi; Maria Cabanillas; Deborah A Thomas
Journal: Blood Date: 2007-01-05 Impact factor: 22.113

3. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.

Authors: Juan-Manuel Sancho; Josep-Maria Ribera; Maria-José Romero; Victoria Martín-Reina; Pilar Giraldo; Elena Ruiz
Journal: Haematologica Date: 2006-03 Impact factor: 9.941

4. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

Authors: M J Glantz; S LaFollette; K A Jaeckle; W Shapiro; L Swinnen; J R Rozental; S Phuphanich; L R Rogers; J C Gutheil; T Batchelor; D Lyter; M Chamberlain; B L Maria; C Schiffer; R Bashir; D Thomas; W Cowens; S B Howell
Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544

5. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

Authors: M J Glantz; K A Jaeckle; M C Chamberlain; S Phuphanich; L Recht; L J Swinnen; B Maria; S LaFollette; G B Schumann; B F Cole; S B Howell
Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531

6. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.

Authors: Kurt A Jaeckle; Tracy Batchelor; Steven J O'Day; Surasak Phuphanich; Pamela New; Glenn Lesser; Allen Cohn; Mark Gilbert; Robert Aiken; Deborah Heros; Lisa Rogers; Eric Wong; Dorcas Fulton; John C Gutheil; Said Baidas; Julia M Kennedy; Warren Mason; Paul Moots; Christy Russell; Lode J Swinnen; Stephen B Howell
Journal: J Neurooncol Date: 2002-05 Impact factor: 4.130

7. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.

Authors: L Bomgaars; J R Geyer; J Franklin; G Dahl; J Park; N J Winick; R Klenke; S L Berg; S M Blaney
Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544

Review 8. Prevention and treatment of meningeal leukemia in children.

Authors: D Pinkel; S Woo
Journal: Blood Date: 1994-07-15 Impact factor: 22.113

9. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.

Authors: M C Chamberlain; P Kormanik; S B Howell; S Kim
Journal: Arch Neurol Date: 1995-09

10. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.

Authors: K A Jaeckle; S Phuphanich; M J Bent; R Aiken; T Batchelor; T Campbell; D Fulton; M Gilbert; D Heros; L Rogers; S J O'Day; W Akerley; J Allen; S Baidas; S Z Gertler; H S Greenberg; S LaFollette; G Lesser; W Mason; L Recht; E Wong; M C Chamberlain; A Cohn; M J Glantz; J C Gutheil; B Maria; P Moots; P New; C Russell; W Shapiro; L Swinnen; S B Howell
Journal: Br J Cancer Date: 2001-01 Impact factor: 7.640

10 in total

5 in total

1. Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model.

Authors: Anna M Thomsen; Maria E Gulinello; Jing Wen; Kjeld Schmiegelow; Peter D Cole
Journal: J Pediatr Hematol Oncol Date: 2018-03 Impact factor: 1.289

2. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

Authors: Nicola Gökbuget; Christina-Maria Hartog; Renato Bassan; Heinz-Gerd Derigs; Herve Dombret; Richard Greil; Jesus-Maria Hernández-Rivas; Francoise Huguet; Tamara Intermesoli; Eric Jourdan; Christian Junghanss; Lothar Leimer; Maria-Jose Moreno; Albrecht Reichle; Josep Ribera; Matthias Schmid; Hubert Serve; Matthias Stelljes; Reingard Stuhlmann; Dieter Hoelzer
Journal: Haematologica Date: 2010-10-15 Impact factor: 9.941